Cabaletta Bio, Inc.
Cabaletta Bio is a U.S. biotechnology company developing engineered T-cell therapies for autoimmune diseases. The company's scientific work combines cellular engineering with clinical development intended to alter harmful immune responses. Its research interests span rheumatologic, inflammatory and antibody-mediated autoimmune disorders, rather than concentrating solely on oncology. Cabaletta is headquartered in Philadelphia, Pennsylvania, and its shares trade on Nasdaq under CABA. The technology involves modifying immune cells for therapeutic purposes and assessing their effects in defined patient populations. Cabaletta's focus places it within the broader field of cell-based medicines and immune-system modulation for serious disease.
Company at a glance
Corporate information
- Company entity
- Cabaletta Bio, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.cabalettabio.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: CABA
autologous CAR-T · engineered T cells
autoimmune diseases · rheumatology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Cabaletta Bio is a U.S. biotechnology company developing engineered T-cell therapies for autoimmune diseases. The company's scientific work combines cellular engineering with clinical development intended to alter harmful immune responses. Its research interests span rheumatologic, inflammatory and antibody-mediated autoimmune disorders, rather than concentrating solely on oncology. Cabaletta is headquartered in Philadelphia, Pennsylvania, and its shares trade on Nasdaq under CABA. The technology involves modifying immune cells for therapeutic purposes and assessing their effects in defined patient populations. Cabaletta's focus places it within the broader field of cell-based medicines and immune-system modulation for serious disease.
Business, technology & evidence
- SecuritiesNasdaq: CABA
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Cabaletta Bio, Inc. ↗Cabaletta Bio, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.